search
Back to results

SVT-40776 in Patients Suffering From Overactive Bladder Syndrome

Primary Purpose

Overactive Bladder (OAB)

Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
SVT-40776
Sponsored by
Salvat
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Overactive Bladder (OAB)

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients suffering from OAB for at least 6 months prior to inclusion

Exclusion Criteria:

  • Pregnant and breastfeeding women
  • Any medical condition or need for co-medication which interferes with the drug under investigation (SVT-40776) or the comparator (tolterodine)

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Secondary Outcome Measures

    Full Information

    First Posted
    July 25, 2007
    Last Updated
    June 7, 2011
    Sponsor
    Salvat
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00507169
    Brief Title
    SVT-40776 in Patients Suffering From Overactive Bladder Syndrome
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2011
    Overall Recruitment Status
    Completed
    Study Start Date
    September 2006 (undefined)
    Primary Completion Date
    September 2007 (Actual)
    Study Completion Date
    September 2007 (Actual)

    3. Sponsor/Collaborators

    Name of the Sponsor
    Salvat

    4. Oversight

    5. Study Description

    Brief Summary
    The study will examine which dose of SVT-40776 is best in terms of efficacy, safety and tolerability compared to placebo and tolterodine

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Overactive Bladder (OAB)

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Interventional Study Model
    Parallel Assignment
    Masking
    Double
    Allocation
    Randomized

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    SVT-40776

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    80 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Patients suffering from OAB for at least 6 months prior to inclusion Exclusion Criteria: Pregnant and breastfeeding women Any medical condition or need for co-medication which interferes with the drug under investigation (SVT-40776) or the comparator (tolterodine)

    12. IPD Sharing Statement

    Learn more about this trial

    SVT-40776 in Patients Suffering From Overactive Bladder Syndrome

    We'll reach out to this number within 24 hrs